Clinical Trials
134 trialsNCT07572136 2026-05-27
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT04088864 2026-05-26
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Stanford University
Phase 1 Completed
NCT04881240 2026-05-26
Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT02443831 2026-05-22
CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
University College, London
Phase 1 Recruiting
NCT07055477 2026-05-22
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04318678 2026-05-19
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT06777979 2026-05-19
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT07257419 2026-05-19
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT06287944 2026-05-18
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Recruiting
NCT06879340 2026-05-14
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
University of Kansas Medical Center
Phase 1 Recruiting
NCT07444632 2026-05-08
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07428486 2026-05-07
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05400109 2026-05-05
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05797233 2026-05-04
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT07565220 2026-05-04
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
University of Pittsburgh
Phase 1 Not yet recruiting
NCT06195891 2026-04-29
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Recruiting
NCT05707273 2026-04-24
CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission
City of Hope Medical Center
Phase 1 Active not recruiting
NCT07166419 2026-04-15
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT05077527 2026-04-14
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
Phase 1 Recruiting
NCT04088890 2026-03-30
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
Phase 1 Completed
NCT02287311 2026-03-23
MABEL
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05359211 2026-03-20
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Active not recruiting
NCT04629729 2026-03-19
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
NCT03494569 2026-03-18
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Suspended
NCT06026319 2026-03-16
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Massachusetts General Hospital
Phase 1 Recruiting
NCT03939026 2026-03-02
ALPHA
Allogene Therapeutics
Phase 1 Completed
NCT03434769 2026-02-27
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT06191887 2026-02-13
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT04848064 2026-02-10
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT05694364 2026-02-06
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03666000 2026-02-02
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Imugene Limited
Phase 1 Recruiting
NCT07367685 2026-01-26
Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
The Second Affiliated Hospital of Fujian Medical University
Phase 1 Not yet recruiting
NCT06326463 2026-01-23
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT04223765 2026-01-20
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT04545762 2026-01-14
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 1 Recruiting
NCT03602157 2026-01-06
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06447987 2025-12-17
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Recruiting
NCT03696784 2025-12-08
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06285422 2025-11-28
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Sana Biotechnology
Phase 1 Active not recruiting
NCT06916767 2025-11-10
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT07225439 2025-11-06
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT05878184 2025-10-02
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Sana Biotechnology
Phase 1 Active not recruiting
NCT05705570 2025-09-25
CARTHIAE-1
Hospital Israelita Albert Einstein
Phase 1 Recruiting
NCT02512497 2025-09-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT07168486 2025-09-11
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
University of Maryland, Baltimore
Phase 1 Enrolling by invitation
NCT05950334 2025-08-22
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Fate Therapeutics
Phase 1 Completed
NCT05653271 2025-08-11
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech, Inc.
Phase 1 Recruiting
NCT04608487 2025-07-30
Axi-cel in CNS Lymphoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting